Expert oncologists Prof. Dominik Modest and Dr Sara Lonardi discuss their takeaways from two key clinical trials presented at ASCO 2025, and the potential implications for clinical practice.

 

The physicians discuss data from the following studies:

  • BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant mCRC (BREAKWATER): progression-free survival and updated overall survival analyses. Elez E, et al. Abstract LBA3500, ASCO 2025
  • CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC: expanded analyses from CheckMate 8HW. Lenz H-J, et al. Abstract 3501, ASCO 2025

 

Clinical takeaways

 

  • BREAKWATER: demonstrated a statistically significant and clinically meaningful improvement in PFS and OS with encorafenib, cetuximab (EC) + mFOLFOX6 and establishes front-line EC and FOLFOX as the new standard of care for BRAF V600E–mutant  mCRC.
  • CheckMate-8HW: NIVO + IPI continued to demonstrate improved PFS vs NIVO in patients with MSI-H/dMMR mCRC across all lines of therapy providing further support for NIVO + IPI as the standard of care for patients with MSI-H/dMMR mCRC

Understand the latest highlights on practice-changing BRAF-mutant colorectal cancer data from the ASCO 2025 conference, accentuating the implementation of the latest data into clinical practice, including real-world evidence data

Prof. Dr Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, after 10 years at the LMU in Munich, Germany, he is a physician at the Charité Universitaetsmedizin Berlin, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Prof. Dr Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy and a full professorship in 2020.  Prof. Dr Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.

Prof. Dominik Modest has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Servier, Amgen, Merck, Sanofi, Lilly, BMS, MSD, AstraZeneca, Pierre Fabre, GSK, Seagen, G1, Onkowissen, COR2ED, Taiho, Takeda, Incyte, Cureteq, 21up, IKF, Medscape, Aptitude Health, Bicara, Rottapharm, Agenus, Regeneron, AIO gGmbH

Dr Sara Lonardi is Chief of the Oncology 1 Unit of Veneto Institute of Oncology (IOV) – IRCCS. She obtained her Medical Degree in 2000 and her Oncology specialization in 2004, both from the University of Padova. She has been actively interested in the care of gastrointestinal cancer patients since 1998, and in 2013 became chief of the GI Cancer Unit, being involved in several international and national clinical trials as Principal Investigator. She was also Chief of Phase I Clinical Trial Unit at IOV-IRCCS and pro tempore Chief of the Oncology 3 Unit at IOV-IRCCS. She has published more than 200 scientific articles in peer-reviewed journals dealing with gastrointestinal cancers clinical and translational research. She is an active member of Associazione Italiana di Oncologia Medica-AIOM, European Society of Medical Oncology-ESMO and American Society of Medical Oncology-ASCO, and member of the Steering Committee of the ACCENT DataBase.

Dr Sara Lonardi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Astellas, Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, GSK, Incyte, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche, Servier, Takeda, Rottapharm Biotech, Beigene, Helion, Fosum Pharma, Nimbus Therapeutics

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts
Brought to you by
GI NURSES CONNECT

GI NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer and Eisai Europe Limited.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.